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Monitoring cancer and aging in vivo remains experi-
mentally challenging. Here, we describe a luciferase
knockin mouse (p16LUC), which faithfully reports
expression of p16INK4a, a tumor suppressor and
aging biomarker. Lifelong assessment of lumines-
cence in p16+/LUC mice revealed an exponential
increase with aging, which was highly variable in
a cohort of contemporaneously housed, syngeneic
mice. Expression of p16INK4a with aging did not
predict cancer development, suggesting that the
accumulation of senescent cells is not a principal
determinant of cancer-related death. In 14 of 14
tested tumor models, expression of p16LUC was
focally activated by early neoplastic events, enabling
visualization of tumors with sensitivity exceeding
other imaging modalities. Activation of p16INK4a
was noted in the emerging neoplasm and surround-
ing stromal cells. This work suggests that p16INK4a
activation is a characteristic of all emerging cancers,
making the p16LUC allele a sensitive, unbiased
reporter of neoplastic transformation.
INTRODUCTION
Although murine models have provided insight into the mecha-
nisms governing senescence and tumorigenesis, the dynamics
of these processes in vivo remain elusive. Genetic engineering
has produced murine systems that faithfully mimic important
aspects of human cancer. However, monitoring disease in these
systems is challenging, particularly in the setting of early
neoplasia. Imaging techniques akin to those used in the clinic
(e.g., MRI, FDG-PET, and ultrasound) are now being applied to
rodent models; however, the specificity, cost, and technical
challenges of these approaches have limited their utility, partic-340 Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc.ularly for early detection and serial imaging. In an attempt to
address these challenges, lineage-specific luminescent and
fluorescent reporters have been employed to dynamically track
tumor growth (reviewed in O’Neill et al., 2010). Although these
alleles have provided insight into the development, progression,
and therapeutic response of de novo tumors, their expression is
not limited to would-be cancer cells but is instead limited to the
lineage from which the tumors originate. In contrast, several
‘‘tumor-specific’’ reporter alleles have been reported in the liter-
ature (e.g., E2f-LUC [Uhrbom et al., 2004],ARF-GFP [Zindy et al.,
2003], ODD-Luc [Goldman et al., 2011; Safran et al., 2006], and
p21-p-luc [Ohtani et al., 2007]), but these models are not ideal
as they are activated at late stages during tumorigenesis, are
limited for in vivo and serial imaging, are specific to the under-
lying tumor genetics, and/or demonstrate high background
with a small dynamic range of expression. Similarly, long-term
monitoring is challenging in the case of murine aging, in which
no validated in vivo biomarkers exist. As a result, the discovery
of genetic modifications and therapeutic interventions that
influence aging currently relies upon costly 2 to 3 year rodent
life span studies. To address these needs, we sought to exploit
the unusual properties of the endogenous p16INK4a promoter.
Expression of p16INK4a functions to limit cell-cycle progression
and to promote cellular senescence in response to multiple
stressors, including oncogene activation, telomere erosion,
reactive oxygen species, and stalled replication forks (Collado
et al., 2007; Sharpless and DePinho, 2007). Expression of
p16INK4a in healthy cells is low, but once induced, p16INK4a binds
and inhibits cyclin-dependent kinase 4/6 (CDK4/6) activity,
thereby promoting a retinoblastoma (RB)-dependent cell-cycle
arrest. This tumor-suppressive mechanism is believed to limit
the growth of would-be neoplasms, and accordingly, the
p16INK4a-CDK4/6-RB axis is disrupted in most, if not all, human
cancers, with inactivation of p16INK4a being the most common
lesion of this pathway (see COSMIC [Forbes et al., 2006]).
Although induction of p16INK4a in response to oncogenic stimuli
results in a beneficial, anticancer outcome, expression of this
tumor suppressor also contributes to aspects of mammalian
aging. Both senescent cells and levels of p16INK4a progressively
accumulate with age (Krishnamurthy et al., 2004; Nielsen et al.,
1999; Zindy et al., 1997) and are associated with a decline in
the replicative capacity of many tissue types (Chen et al.,
2011; Janzen et al., 2006; Krishnamurthy et al., 2006; Liu et al.,
2011; Molofsky et al., 2006). As such, human polymorphisms
affecting p16INK4a expression influence susceptibility to multiple
age-associated diseases (e.g., cancer, type 2 diabetes, and
atherosclerosis) (Jeck et al., 2012). Further supporting a causal
role for p16INK4a in aging, measures to reduce the formation
of or to destroy p16INK4a-expressing cells in mice have been
shown to ameliorate several age-associated phenotypes (e.g.,
cataracts, sarcopenia, and pancreatic b cell dysfunction) (Baker
et al., 2011; Berent-Maoz et al., 2012; Carlson et al., 2008; Chen
et al., 2011).
Exploiting the highly dynamic induction of p16INK4a observed
in response to oncogenic insult and senescence, we generated
an in vivo reporter system, p16LUC. In contrast to previous
transgenic reporter systems driven by fragments of the
p16INK4a promoter (Baker et al., 2011; Yamakoshi et al., 2009),
we elected to employ a targeted ‘‘knockin’’ strategy that
preserves known cis-regulatory elements centromeric to the
p16INK4a open reading frame (Visel et al., 2010; Witcher and
Emerson, 2009). We employed this p16LUC allele to monitor
senescence and the earliest steps of tumorigenesis in well-
defined murine systems.
RESULTS
Generation and Characterization of the p16LUC Allele
To generate the p16LUC allele, the firefly luciferase complemen-
tary DNA (cDNA), followed by an SV40 polyadenylation signal,
was targeted into the translational start site of the endogenous
p16INK4a locus (Figure 1A). The resulting knockin allele was ex-
pected to be null for p16INK4a expression yet to retain intronic
structures surrounding exon 1a. After validation of targeting by
Southern analysis and PCR (Figures S1A and S1B available on-
line), we tested the functionality of the allele by culturing p16+/+,
p16+/LUC, and p16LUC/LUC murine embryo fibroblasts (MEFs) on
a 3T3 schedule with serial assessment of growth, luminescence,
and Ink4/Arf gene expression. In accord with prior results
(Krimpenfort et al., 2001; Sharpless et al., 2001), MEFs of each
genotype displayed similar growth kinetics at early passage
(Figure S1C). Moreover, transcription of p19ARF and p15INK4b
was not altered by luciferase insertion into exon 1a of the
Ink4a/Arf locus (Figures S1D and S1E). As expected, no endog-
enous p16INK4a mRNA or protein was detected in p16LUC/LUC
cells, and expression was reduced by 50% in p16+/LUC cells
(Figures 1B–1D). Cultured p16+/LUC and p16LUC/LUC MEFs
showed rapid increases in luciferase activity with passage, ex-
ploiting the full dynamic range of this assay (Figure 1E). For
example, luminescence was initially low in p16LUC/LUC cells
(300 light units/105 cells) but increased more than 150-fold
(>50,000 light units/105 cells) after 2 weeks in culture (Figure 1E).
Induction of p16LUC closely paralleled transcription of the wild-
type allele in p16+/LUC MEFs (Figure 1F, r2 = 0.81, p < 0.0001),
and the absolute level of luciferase transcript was nearly identical
to that of the native p16INK4a transcript (data not shown).Next, we sought to validate the proper expression of p16LUC
in vivo through examination of two physiological processes
previously associated with p16INK4a activation: wound healing
and mammary involution. To achieve optimal sensitivity during
serial assessments, the p16LUC allele was backcrossed onto
a hairless, immunocompetent strain, SKH1-E. As has been re-
ported for endogenous p16INK4a expression (Gadd et al., 2001;
Jun and Lau, 2010; Natarajan et al., 2003), luminescent signal
increased focally during bothwound healing andmammary invo-
lution (Figures 1G and 1H) and resolved upon completion of
these processes. Together, these results show that the p16LUC
targeting strategy produced an allele null for p16INK4a expression
without affecting the production of p15INK4b and p19ARF. More-
over, induction of p16LUC both in vitro and in vivo faithfully and
robustly reported endogenous p16INK4a expression.
p16LUC Activation Correlates with Chronological Aging
but Fails to Predict Cancer Death
Increases in p16INK4a are associated with cellular senescence
and correlate with chronological age in mammals (Krishnamur-
thy et al., 2004; Nielsen et al., 1999; Zindy et al., 1997). To
determine more precisely the relationship between p16INK4a ex-
pression and age, we serially analyzed luminescence in p16+/LUC
mice during physiologic aging. Total body luciferase (TBL)
activity was monitored every 2 months beginning at 16 weeks
of age (young adulthood) in a large cohort of p16+/LUC animals
(n = 32). In this cohort, but not in a contemporaneously analyzed
group of p16+/+ animals, TBL activity increased during a period
of 80 weeks (Figures 2A, 2B, and S2A; average 6.9-fold increase
from 16 to 80 weeks of age). Likewise, luciferase mRNA levels,
detected by using single-molecule in situ hybridization,
increased in the epidermal keratinocytes and dermis of aged
murine skin in comparison to young controls (Figure 2C). These
data confirm previous findings regarding p16INK4a expression
in aging tissues (Dimri et al., 1995; Jeyapalan et al., 2007; Krish-
namurthy et al., 2004; Ressler et al., 2006; Waaijer et al., 2012;
Zindy et al., 1997), showing that p16LUC reports faithful, age-
related increases in gene expression.
Given the ability of p16LUC to serially assess aging in vivo,
we next compared the dynamics of p16INK4a induction with
chronological aging. Analysis of aggregate data collected during
80 weeks demonstrated a strong, linear correlation (r2 = 0.963)
between log2-transformed luminescence and chronological
age, indicating exponential growth with a ‘‘p16INK4a-doubling
time’’ of 0.45 years (Figure S2A). By using combined data of
p16INK4a expression in T cells from two cohorts of healthy human
donors aged 18–91 (n = 208) (Liu et al., 2009; H.B. Muss et al.,
2011, J. Clin. Oncol., abstract), we estimated the average human
p16INK4a-doubling time to be 17.8 years (Figure S2B). These data
suggest that the ratio of human/mouse p16INK4a-doubling time
(40-fold) is similar to the human/mouse ratio of median and
maximal life span (Austad, 1997). Moreover, the rate and expres-
sion of p16LUC did not differ significantly between genders,
although females appeared to have slightly higher p16LUC levels
early in life (p = 0.094; Figure S2C). Interestingly, even in this
cohort of contemporaneously housed, syngeneic mice, we
observed significant interindividual variability in the rate of
change in luminescence with aging (Figures 2A and S2D),Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc. 341
Figure 1. Design and Validation of the p16LUC Allele
(A) Schematic of the p16LUC knockin targeting strategy. ‘‘+ Flp’’ denotes the targeted allele after Flp-recombinase-mediated excision of the neomycin selection
cassette.
(B) Induction of p16INK4a mRNA is shown in MEFs of indicated genotypes passaged on a 3T3 schedule. Fold induction was calculated with respect to p16INK4a
transcript levels at day 3. Data shown correspond to three biological replicates performed in triplicate. Error bars represent SEM.
(C) p19ARF and p16INK4a western blots for littermate MEFs cultured on a 3T3 schedule and harvested at the indicated time points.
(D) Fold p16INK4a induction is shown for the western blots represented in (C). Bands were quantified by using a LICOR Odyssey system, normalized to total
protein, and analyzed as in (B).
(E) Luciferase activity in MEFs of the indicated genotypes, with results calculated and presented as in (B). Error bars are ±SEM.
(F) Correlation of luciferase activity and endogenous p16INK4a expression in p16+/LUCMEFs passaged on a 3T3 schedule. Data representR3 biological replicates
at multiple in vitro time points with best-fit line and 95% confidence intervals (dashed lines) shown. Linear regression was used to calculate the p value and
correlation coefficient (r).
(G) Representative, 2 min luminescent images of a lactating p16+/LUC mouse at the indicated time points relative to the weaning date (WD).
(H) Representative, 2 min photographic and luminescent images of a p16+/LUC mouse with healing wounds.
See Figure S1 for additional related data.demonstrating a considerable nongenetic contributor to the rate
of molecular aging.
Based upon extensive work from our group and others sug-
gesting that age-related phenotypes, including cancer, are
promoted by the accumulation senescent cells (Baker et al.,
2008, 2011; Bavik et al., 2006; Berent-Maoz et al., 2012; Campisi
et al., 2011; Chen et al., 2011; Coppe´ et al., 2008; Kang et al.,
2011; Krishnamurthy et al., 2006; Krtolica et al., 2001; Laberge
et al., 2012; Liu and Hornsby, 2007; Liu et al., 2011; Molofsky
et al., 2006; Parrinello et al., 2005), we hypothesized that342 Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc.p16LUC expression with aging would predict mortality. If correct,
p16+/LUC animals with the highest total body luminescence
should be more likely to develop age-related phenotypes than
age-matched mice with lower p16LUC expression. Exploiting
the large heterogeneity in luciferase activity at any given time
point in our aging cohort, we were able to directly test this
assumption. However, in contrast to expectation, total body
p16LUC expression failed to predict two age-related phenotypes:
overall mortality and development of spontaneous malignancy.
Imaging 4–6 weeks prior to an animal’s terminal event (death
Figure 2. Induction of p16LUC Correlates with Age, but Not with Life Span
(A) Total body luciferase activity in hairless (SKH1-E) p16+/LUCmice quantified using a 2min, ventral image and plotted versus age (n = 32). The blue line represents
themedian value for each time point. Luciferase activity in 80-week-old p16+/+mice is shown for comparison. For statistical analyses, at each time point, the ratio
of total body luminescence relative to week 16 was calculated. Wilcoxon signed-rank tests were used to test whether each ratio was significantly different than 1.
p < 0.0001 for all comparisons except week 24 (p = 0.018).
(B) Representative serial luciferase images of mice from the study shown in (A). Each 2min image shows the same group of mice, arranged identically. Mouse 2 is
p16+/+, whereas all other mice are p16+/LUC.
(C) Skin from the hind quarter of old and young p16+/LUC animals was fixed in the same paraffin block and subjected to single-molecule luciferase RNA in situ
hybridization. Shown are representative images of tissues from the same paraffin block with luciferase message appearing as brown dots. Original magnifi-
cation = 403.
(D) The average total body luciferase activity for the cohort shown in (A) is plotted in blue with 95% confidence intervals depicted by dotted lines. Plotted in black
are points representing total body luciferase activity in the image preceding the life span event (death of tumor formation) for each mouse (n = 14).
(E) Total body luciferase activity was calculated for each livingmouse at 56 weeks of age. Using themedian luciferase activity at this time point, mice were divided
into high and low groups. Kaplan Meier curves for each group are shown with p values calculated by using a log rank test.
(F) By using linear regression, the rate of luciferase increase was calculated for each mouse alive at 56 weeks. By using the median rate of increase at this time
point, mice were divided into high and low groups. Kaplan Meier curves for each group are shown, and p values were calculated by using a log rank test.
See Figure S2 for additional related data.or euthanasia for overt tumor formation) showed no increase
in p16LUC activity compared to surviving age-matched contem-
poraries (Figure 2D). Additionally, after excluding animals with
wounds or cancer and stratifying our cohort into groups with
higher- or lower-than-median luminescence, Kaplan Meier anal-
ysis showed that animals with higher total body luminescence
at any age exhibited the same overall mortality rates as those
with lower total body luminescence (Figures 2E and S2E–S2G).Likewise, the rate of change in luminescence activity at any
age was not predictive of death (Figures 2F and S2H–S2J).
Consistent with previous assessments of mortality in several
strains of inbred as well as outbred mice (Chrisp et al., 1996;
Miller et al., 2011; Wilkinson et al., 2012), all autopsied animals
from the study showed signs of advanced cancer. Moreover,
no significant decrease in median survival was observed
between p16+/+ and p16+/LUC animals (Figure S2K). Therefore,Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc. 343
these findings demonstrate that total body expression of
p16INK4a, an accepted in vivo marker of cellular senescence,
does not, at any age, predict the risk of death from spontaneous
malignancy during normal murine aging.
p16LUC Signals Cancer
We next turned to a study of p16INK4a induction in early neoplasia
by crossing the p16LUC allele to well-characterized, genetically
engineered mouse models of autochthonous cancer: C3(1)TAg
(basal-like breast cancer driven by SV40 large T-antigen [Tag])
(Herschkowitz et al., 2007; Maroulakou et al., 1994) and TRIA
(Tyr-RasG12V, Ink4a/Arf/ melanoma) (Chin et al., 1997).
Notably, TRIA mice harboring the p16LUC knockin allele are null
for functional p16INK4a (p16/LUC) but retain a single copy of
p19ARF in cis to the targeted luciferase allele. However, we
have labeled TyrRasG12V p16/LUC Arf/+ mice TRIA for the
sake of brevity. Of note, C3(1)Tag mice also develop mixed ec-
crine sweat gland tumors of the paw in addition to mammary
tumors (Maroulakou et al., 1999) (Figure S3A). The resulting
cohorts were monitored biweekly, starting at young adulthood.
Luminescent activity was not apparent in young p16+/LUC or
p16/LUC mice harboring these oncogenic transgenes; but with
aging, intense, highly focal regions of luminescence developed
within the mammary glands and paws of C3(1)TAg mice or the
skin of TRIA mice (Figures 3A–3D and S3A). These regions
showed focal luminescent intensities >10 times higher than
that observed with aging, clearly distinguishing them from age-
related p16INK4a activation (Figure S3B). On average, 62 days
later (range = 0–408 days), tumors developed in these precise
locations, providing an earlier and more dynamic means of
identifying neoplastic growth than traditional methods (Figures
3E–3G and S3C). No difference in luminescence activity was
observed between age-matched p16+/LUC and tumor-free
p16/LUC TRIA mice (Figure S3D), suggesting that oncogene
activation in melanocytes alone was not sufficient to induce
marked p16INK4a expression. Instead, subsequent events asso-
ciated with neoplastic conversion appeared to trigger p16LUC
transcription.
When initially noted, luminescent foci of the skin (TRIA) or
breast (C3(1)TAg) appeared normal visually and by palpation.
Therefore, we further explored the tumor detection advantage
provided by the p16LUC allele. On average, luminescent foci
were discovered 41 (C3(1)TAg; range: 14–73) or 87 (TRIA; range:
0–408) days before the tumors became palpable or visible
(Figures 3E–3G). Representative tumors visualized by lumines-
cence, but not yet palpable, were excised from p16+/LUC C3(1)
TAg mice and measured. An unequivocal luminescence signal
was detectable in mice with tumors as small as 1 mm3 (Figures
3H and 3I). Moreover, comparison of fluorodeoxyglucose posi-
tron emission tomography (FDG-PET) with luminescence detec-
tion revealed increased specificity and sensitivity by using
p16LUC as a tumor detectionmodality (Figure 3J). Signal intensity
was not uniform in tumors of the same size from different
animals, owing to interanimal differences in tumor biology and/
or technical features related to imaging (e.g., tumor location)
(Figure S3E). Subsequent analysis of de novo C3(1)TAg tumors
by using luciferaseRNA in situ hybridization confirmed activation
of the p16INK4a promoter in the early stages of neoplasia, prior to344 Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc.detectability by total body luminescent imaging (Figure S5B).
Therefore, use of the p16LUC allele provides a detection advan-
tage over conventional modalities, allowing for the visualization,
excision, and analysis of de novo tumors at considerably earlier
stages.
Unbiased Tumor Detection with p16LUC
Use of p16LUC to detect de novo tumor formation was not limited
to genetically engineeredmousemodels harboring defects in the
RB tumor suppressor pathway. Melanomas driven by oncogenic
K-RasG12D (Liu et al., 2012) or B-RafV600E (Dankort et al., 2009),
as well as hematological malignancies caused by Myc overex-
pression (Harris et al., 1988), displayed intense, focal lumines-
cent signals (Figures S4A–S4C). In addition, spontaneous
tumors arising in aged p16+/LUC mice were readily detected
(Figures 4A, 4B, and S4D). Not only were primary tumors easily
detectable in these mice, but spontaneous hematologic malig-
nancies disseminated to the brain, bone marrow, spleen, and
liver were also routinely observed (Figures 4A and S4D). In
fact, testing of 14 different tumors models failed to identify
a tumor type wherein p16LUC is not focally induced in emerging
tumors (Table S1). Taken together, these data suggest that
activation of p16LUC marks the vast majority of, if not all, malig-
nancies, independent of cell type or driver mutation.
Non-Cell-Autonomous Activation of p16LUC
To address the contribution of p16LUC expression in tumor
versus tumor-associated stroma, we performed orthotopic
transplantation of C3(1)TAg tumor cells without the p16LUC allele
into syngeneic p16+/LUC mice (Figure 5A) and then serially
imaged these animals at early stages of tumor formation. Strik-
ingly, induction of p16LUC was observed in the area of tumor
formation, but not in the contralateral, matrigel-injected
mammary gland. Moreover, injection with MEFs failed to induce
p16LUC (Figure S5A), demonstrating that stromal p16INK4a activa-
tion is triggered by local malignant growth. To assess the univer-
sality of stromal p16LUC induction, we transplanted five different,
syngeneic nonluminescent tumor cell lines (two breast, one
pancreatic, one endometrial, and one lung) harboring diverse
oncogenic driver mutations (Lkb1 loss, p53 loss, K-RasG12D,
and Her2-Neu overexpression) into p16+/LUC recipients (Figures
5B and S5A). In all cases, luciferase activity localized to the site
of tumorigenesis but was not observed in the vehicle-injected
control. Furthermore, examination of de novo C3(1)TAg tumors
by using luciferase RNA-ISH showed activation of p16LUC in
the stroma surrounding early neoplastic lesions (Figure S5B).
Together, these results provide evidence that extrinsic signals
present in an emerging tumor induce local, non-cell-autono-
mous p16INK4a expression.
To establish whether the host hematopoietic system contrib-
utes to the p16LUC signal in transplanted tumors, FVB/n mice
underwent lethal irradiation and bone marrow transplantation
with total marrow from syngeneic p16+/LUC donors (Figure 5C).
Following engraftment, mice were orthotopically injected with
syngeneic C3(1)TAg tumor cells lacking the p16LUC allele. Two
months after bone marrow transplantation, luciferase imaging
revealed strong induction of p16LUC, specifically in the area
of tumor formation (Figure 5C). These results indicate that
Figure 3. p16LUC Marks Early, De Novo Tumorigenesis
(A) Representative serial images showing p16LUC accumulation at p16+/LUC, C3(1)TAg+ tumor foci during a period of 8 weeks. Several focal, mammary, and paw
tumors are visible. A palpable tumor, smaller than could be measured by calipers, is highlighted in the red box.
(B) Representative serial images showing p16LUC accumulation at a p16/LUC TRIA ear tumor during a period of 6 weeks.
(C) Haematoxylin and eosin staining showing the morphology of the TRIA ear tumor shown in (B).
(D) Haematoxylin and eosin staining showing the morphology of the barely palpable C3(1)TAg tumor highlighted in (A).
(E) The number of days prior to palpation or visualization where luciferase activity was observed in tumors of p16+/LUC C3(1)TAg mice. Data are shown for
individual tumors with the median detection advantage indicated by a line.
(F) The number of days prior to palpation or visualization where luciferase activity was observed in tumors from p16/LUC TRIAmice. Data are depicted as in (E).
(G) Combined Kaplan-Meier analysis of tumor-free survival in p16+/LUC C3(1)TAg and p16/LUC TRIA mice by using tumor detection by either luminescence or
palpation. Significance was determined by using a log rank test.
(H) Luciferase images of a p16+/LUC C3(1)TAg mouse with early mammary tumors (2 min ventral image, 1 min side image).
(I) Photographic images of mammary tumors dissected from the mouse in (H) and (J). Ruler hash marks represent 1 mm units.
(J) FDG-PET images of the same p16+/LUC C3(1)TAg mouse shown in (H). Tumor 1 is not visualized by FDG-PET.
See additional supporting data in Figure S3.neoplasia either induces p16INK4a expression in infiltrating hema-
topoietic cells or recruits p16INK4a-expressing bone-marrow-
derived cells to the developing tumor.
DISCUSSION
This work establishes the p16LUC knockin allele as a faithful
reporter of p16INK4a transcriptional activation in vivo. We have
used this system to serially assess the activation of p16INK4a
with aging, tissue wounding, breast involution, and neoplasticprogression. Surprising findings from these analyses are the
lack of association between organismal expression of a cellular
senescencemarker and cancer-related mortality and the potent,
nonautonomous induction of p16INK4a in the benign stroma of
a nascent neoplasm.
Expression of p16INK4a has been considered one of the best
in vivo markers of cellular senescence. Although activation of
p16LUC directly correlated with chronological age in our cohort
(Figures 2A and S2A), we observed a surprising variability in total
body p16INK4a expression. For example, in 80-week-old mice,Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc. 345
Figure 4. p16LUC Activity Detects Spontaneous Cancers In Vivo
(A) (Top) Detection of a spontaneous histiocytic malignancy in a 110-week-old p16+/LUC mouse. All luminescent images shown were 1 min in length except
the ventral image, which was 2min long. Organ images were taken immediately following imaging. (Bottom) Haematoxylin and eosin stained fixed tissues confirm
the presence of malignancy within luciferase positive regions of the brain and liver.
(B) (Top) Luminescent detection of a spontaneous, disseminated lung adenocarcinoma in a 78-week-old p16+/LUC mouse. Images were generated as in (A) with
confirmatory histology shown below.
See also Figure S4 and Table S1.total body luminescence differed by a factor of 10 between the
highest- and lowest-expressing mice. We used this heteroge-
neity in expression to directly test whether a common age-
associated phenotype, risk of spontaneous malignancy, was
predicted by the in vivo activation of p16INK4a, a classical indi-
cator of cellular senescence. In contrast to our expectations,
total body luminescence and the rate of change in luminescence
were not predictive of mortality (Figures 2A, 2B, 2D–2F, S2A, and
S2E–S2J). In accord with prior work (Chrisp et al., 1996; Miller
et al., 2011; Wilkinson et al., 2012), all deaths in our cohort
appeared to result from malignancy. Therefore, this analysis
indicates that total body expression of amarker of cellular senes-
cence is not associated with an important age-associated
phenotype: risk of developing cancer.
This finding is not the predicted result. Work from several
groups, including our own, has shown that the accumulation of
p16INK4a-positive and/or senescent cells in vivo promotes
numerous age-related phenotypes (Baker et al., 2008, 2011;
Berent-Maoz et al., 2012; Chen et al., 2011; Krishnamurthy
et al., 2006; Liu et al., 2011; Molofsky et al., 2006), including
tumorigenesis (Bavik et al., 2006; Campisi et al., 2011; Coppe´
et al., 2008; Kang et al., 2011; Krtolica et al., 2001; Laberge
et al., 2012; Liu and Hornsby, 2007; Parrinello et al., 2005). We
believe there are two ways to reconcile these prior results with
the present work. First, we show that p16INK4a expression
reports tissue insults that may not represent cellular senescence
(e.g., tissue wounding). It is therefore formally possible that the
massive, stereotypical increase in p16INK4a expression noted
with aging in all mammals does not reflect the accumulation of
senescent cells but rather indicates cellular stresses indepen-346 Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc.dent of senescence. This would be surprising to the field given
the extensive body of work suggesting that p16INK4a expression
is one of the most reliable and robust markers of senescence
in vivo in both murine and human tissues (Baker et al., 2011; Ed-
wards et al., 2007; Koppelstaetter et al., 2008; Krishnamurthy
et al., 2004; Lemster et al., 2008; Liu et al., 2009; Melk et al.,
2004; Nielsen et al., 1999; Signer et al., 2008; Waaijer et al.,
2012; Zindy et al., 1997). The finding that p16INK4a does not faith-
fully report senescence in vivo would undermine the majority of
prior work describing senescence in intact organisms, particu-
larly studies in mice. More likely, we believe these data indicate
that spontaneous cancer, which was the cause of death in our
colony, is not caused by the accumulation of senescent cells
and the expression of cytokines related to the senescence-
associated secretory phenotype (SASP). A caveat to this
analysis is that spontaneous human malignancies differ from
cancers of experimentally housed mice in important ways such
as time to progression and degree of aneuploidy, and it is
possible that SASP cytokines play a more critical role in human
tumor progression.
We did not examine age-related phenotypes other than
cancer susceptibility and mortality. Therefore, our results do
not contradict the view that some age-related phenotypes
(e.g., decreased T cell replication [Liu et al., 2011] and sarcope-
nia [Baker et al., 2011]) are associated with p16INK4a activation,
senescence, and the elaboration of SASP factors. For example,
Van Deursen and colleagues recently demonstrated the
amelioration of several age-associated phenotypes in progeroid
mice through the in vivo clearance of senescent cells (Baker
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Figure 5. p16LUC Activity Signals Cancer via
Non-Cell-Autonomous Mechanisms
(A) Immune competent, FVB/N p16+/LUC mice were
injected orthotopically as depicted with syngeneic
p16+/+ C3(1)TAg cells in matrigel or matrigel vehicle
alone and imaged upon tumor establishment. A
representative 2 min image is shown.
(B) Syngeneic p16+/+ breast (MMTV-HER2/Neu and
K14-CRE p53Lox/Lox), pancreatic (Pdx-CRE LSL-K-
rasG12D p53Lox/Lox), and endometrial (Sprr2f-CRE
Lkb1Lox/Lox) cancer cell lines were injected subcu-
taneously into p16+/LUC mice and imaged upon
tumor establishment. Representative 2 min lumi-
nescent images are shown for each model.
(C) Syngeneic transplantations of p16+/LUC bone
marrow into p16+/+ recipients were conducted
as depicted. Following immune reconstitution,
syngeneic p16+/+ C3(1)TAg cells were orthotopi-
cally transplanted into the mice and imaged as in
(A). Tumor size at the time of imaging is noted.
Robust luciferase activity was seen in all trans-
planted tumors, but not in contralateral sites in-
jected with matrigel only.
See also Figure S5.span, in accord with our present findings. We continue to believe
that the measurement of p16INK4a expression in human tissues
will be of clinical value to predict regenerative decline (Koppel-
staetter et al., 2008; Liu et al., 2009; McGlynn et al., 2009; Nelson
et al., 2012), but our findings represent an important step in
reconciling which age-associated phenotypes result from the
in vivo accumulation of senescent cells and which (such as
development of murine cancers) do not.
We demonstrate that the p16LUC allele is an unexpectedly
robust detector of nascent tumorigenesis. Although cancer
reporter systems have been published that are tissue specific
or require ex vivo transduction (reviewed in O’Neill et al., 2010),
the apparent universality and early detection capabilities of
this system provide significant advantages. Tumor detection
by p16LUC is independent of CRE recombinase expression,
allowing this system to be used to monitor carcinogen-induced
and spontaneously arising cancers (Figures 3, 4, S3A, and
S4A–S4D; data not shown). Unlike previous cancer reporters,Cell 152, 340–35p16LUC appears to function robustly in
tumors of any genetic background or
tissue type. To wit, we have observed
activation of the p16INK4a promoter in 14
distinct cancer models, including trans-
genic autochthonous, transplanted, and
spontaneous tumors (see Table S1 and
Figures 3, 4, 5, S3, S4, and S5), and we
have yet to identify a neoplasm that is not
associated with p16INK4a induction. Even
using furred, heterozygous p16LUC mice,
we noted a distinct spatial and temporal
advantage over standard approaches
(i.e., FDG-PET and palpation) (Figures
3H–3J), with better results noted in hair-
less, p16LUC/LUC mice. Preliminary resultsusing tail vein injection of syngeneic cancer cells show that
internal tumors can be readily detected by p16LUC (data not
shown), suggesting that the reporter will also be of value to
studies of metastatic spread. However, we have yet to test the
allele in a setting of true de novo metastasis. Given the versatility
of p16LUC, we believe this reporter will be generally useful for
early cancer detection, serial assessment of tumor progression,
and anticancer compound testing.
We believe two features of this system account for its utility in
the detection of early cancers. First, prior work has shown that
the p16INK4a promoter is unusually dynamic in vivo (Krishnamur-
thy et al., 2004), and accordingly, we note a >150-fold change
in luminescence during the serial passaging of p16+/LUC MEFs
(Figure 1E). We believe this massive increase in expression on
a per cell basis underlies the allele’s sensitivity, allowing for
in vivo detection of extremely small tumors (Figures 3H–3J and
S5B). Second, robust induction of p16INK4a in the stroma of
developing neoplasia amplifies the tumor-specific signal and1, January 17, 2013 ª2013 Elsevier Inc. 347
occurs regardless of a given tumor’s driver genetics (Figures 5
and S5). The resulting focal, sustained, and intense signal allows
emerging neoplasms to be readily distinguished from p16INK4a
increases associated with aging and other nonmalignant states
(e.g., wound healing) (Figure S3B).
Since the original observation that oncogenes induce senes-
cence in part through upregulation of p16INK4a (Serrano et al.,
1997), research has largely focused on cell-intrinsic activators
of p16INK4a expression such as DNA damage (Pavey et al.,
1999), telomere shortening (Bartkova et al., 2006; Jacobs and
de Lange, 2004), production of reactive oxygen species (Ito
et al., 2004), and stalled replication forks (Ressler et al., 2006).
These results indicate that p16INK4a also responds to extrinsic
‘‘field effects’’ present within every type of emerging neoplasm
thus far examined. Additionally, this work speaks to the cell-
intrinsic/extrinsic debate that pervades mammalian gerontology
as we show that an emerging neoplasm triggers local, non-
cell-autonomous expression of a validated effector of cellular
senescence. Indeed, non-cell-autonomous factors (e.g., Wnt/
b-catenin, Hh/Gli, PDGF, and IL-7) have been reported to regu-
late p16INK4a expression as a potential means of developmental
control (Berent-Maoz et al., 2012; Bishop et al., 2010; Chen
et al., 2011). Whether such extrinsic signals also serve to induce
p16INK4a expression and cellular senescence in the context of
normal aging remains to be established.
In summary, the p16LUC system represents a substantial
advance for cancer and aging studies that use the mouse as
a model system. The system also allows for simple, serial, and
noninvasive assessment of expression of p16INK4a in vivo, which
is a critical step in the activation of cellular senescence. The
allele’s utility reflects the highly dynamic range of p16INK4a ex-
pression in vivo as well as the unexpected finding of p16INK4a
activation in tumor-associated, nonmalignant stroma, thereby
allowing the allele to report emergence of every tumor type
tested, regardless of the underlying tumor genetics. As cellular
senescence is a principal barrier to tumorigenesis and contrib-
utes to mammalian aging, the p16LUC system will be a valuable
asset for the serial assessment of cancer and aging, as well for
the testing of pharmacological interventions intent on altering
these processes in vivo.
EXPERIMENTAL PROCEDURES
Husbandry and Generation of the p16LUC Allele
Animal work was conducted in accordance with protocols approved by the
institutional care and use committee for animal research at the University of
North Carolina. Standard homologous recombination procedures were used
to target firefly luciferase, followed by an SV40 polyadenylation site to exon
1a of the endogenous p16INK4a gene. The primers and conditions used for
p16LUC genotyping were as follows: p16-LUC-F 50-CTATGGCGGGCTGTG
GAG-30 (0.15 mM); p16-LUC-R 50-CACGGTAGGCTGCGAAATG-30 (0.15 mM),
p16-LUCR3 50 30 (0.2 mM); 95C for 15 min, 363 [94C for 30 s, 58C for
30 s, and 72C for 45 s], 72C for 2 min. The resulting PCR products are
312 (wild-type) and 543 (p16LUC) base pairs long.
Cell Isolation, Culture, and Detection of Endogenous Ink4a/Arf
Transcripts
MEFs were generated from p16LUC heterozygous parents by using a Gentle-
MACS dissociator (Miltenyi Biotec, Germany). Briefly, embryos were har-
vested, chopped coarsely in 0.5% trypsin-EDTA, and then allowed to digest348 Cell 152, 340–351, January 17, 2013 ª2013 Elsevier Inc.for 5–10 min. Cells were then placed into a GentleMACS C-tube, and program
‘‘A’’ was used twice in succession to generate single-cell suspensions. A
similar protocol was used to generate tumor cell lines from the C3(1)TAg
and TRIA models.
MEFs, C3-TAg, PDAC1 (Bardeesy et al., 2006), and Kp53 (murine lung
adenocarcinoma cells, gift of W.Y. Kim, UNC) cells were cultured in DMEM
supplemented with 4.5g/l glucose, 10% fetal bovine serum (FBS), 1% peni-
cillin streptomycin, and 2 mM L-glutamine. Her2/Neu-overexpressing NT2
cells were cultured in RPMI-1640 supplemented with 20% FBS, 2 mM
L-glutamine, 12 mM HEPES, 0.1 mM NEAA, 1 mM sodium pyruvate, 1% peni-
cillin streptomycin, 50 mM b-mercaptoethanol, and 0.2 units/ml Novolin
R-insulin. Endometrial Lkb1 null tumor lines derived from metastatic tumors
in Sprr2f-CRE Lkb1Lox/Lox females (Contreras et al., 2010) were cultured in
DMEM with low glucose supplemented with 110 mg/l pyruvate, 10% FBS,
2 mM L-glutamine, and 13 antibiotic antimycotic (15240, Invitrogen).
RT-PCR strategies for the detection of Ink4a/Arf transcripts were previously
described (Burd et al., 2010; Krishnamurthy et al., 2004). Western blots em-
ployed the following antibodies and were quantified on a LICOR Odyssey
system: p16INK4a (Santa Cruz M126; 1:500), p19ARF (Abcam AB80; 1:1,000).
In Vivo and In Vitro Luciferase Detection
Isoflurane-anesthetized mice were injected intraperitoneally with D-luciferin
substrate (Caliper Life Sciences; 15 mg/ml in PBS) and were imaged by using
an IVIS Lumina or IVIS Kinetic system (Caliper Life Sciences). Peak lumines-
cence was determined to begin 6–8 min after substrate administration. To
ensure that analysis was performed at the same time point, a set sequence
of sequential images between 10 s and 2 min in length was begun immedi-
ately after intraperitoneal injection of D-luciferin. A wide-angle lens was used
to simultaneously capture images from >3 animals. Images were taken by
using a binning of 4 (medium). For tumor studies in which mice were approx-
imately the same size, 300 ml of substrate was administered. In aging studies,
in which animal size varied, mice were injected with 10 ml/g body weight of
substrate. Living Image Software (Caliper Life Sciences) was used to
compare multiple images taken at the same exposure and time point
following substrate administration. For all analyses, an additional ROI was
employed to normalize for background luminescence on each image.
In vitro luciferase assays were conducted by using a standard approach
and were normalized for cell number. RNA-ISH was conducted by using
RNAscope 2.0 technology as described by the manufacturer (Advanced
Cell Diagnostics).
Analysis of Luminescence with Aging
Beginning at 16 weeks of age (adulthood), mice were imaged bimonthly in
groups of three to five, as above. Analysis was conducted on 2 min ventral
images taken 6min after D-luciferin administration. The contour of eachmouse
was traced, and the flux/pixel was determined by using Living Image Software
(Caliper Life Sciences). Flux/pixel was also calculated for an unoccupied
region of the image and subtracted from the traced area as background.
Images were excluded from the analysis if a mouse had visible wounds.
Animals were only allowed to re-enter the study upon complete wound reso-
lution. Focal luminescent intensity in the mesenteric and cervical lymph nodes
was common in healthy mice of all ages. However, intense luminescent signal
in other areas of the body was often indicative of tumor formation; therefore,
these images were excluded from analysis (see example in Figure 2B). Never
did these ‘‘tumor regions’’ resolve. As such, these mice never re-entered the
study. Of the 32 p16+/LUC mice in this study, the number excluded or dead
at each time point was the following: 16 weeks, 0; 24 weeks, 1; 32 weeks, 1;
40 weeks, 2; 48 weeks, 2; 56 weeks, 2; 64 wks, 3; 72 weeks, 7; and 80 weeks,
12. Kaplan-Meier analysis showed no significant difference between the life
span of p16+/+ and p16+/LUC mice in our cohort (Figure S2K), suggesting that
p16INK4a heterozygous animals were as susceptible to cancer-related death
as their wild-type counterparts in this study.
Genetically Engineered Tumor Models
Female C3(1)TAg animals express SV40 large T-antigen (TAg) from the rat C3
promoter and develop mammary tumors with transcriptional profiles resem-
bling human basal-like breast cancers (Herschkowitz et al., 2007; Maroulakou
et al., 1994) as well as salivary and mixed eccrine sweat gland tumors of the
paws (Maroulakou et al., 1999). TRIA mice are germline null for the Ink4/Arf
locus and express oncogenic H-RasG12V from the melanocyte-specific tyros-
inase promoter (Chin et al., 1997) (NCI Mouse Repository strain 01XB1). TRIA
mice analyzed in this work were Arf+/ and were therefore not fully deficient for
Arf function (see Results). The Em-Myc model was obtained from Jackson
Laboratories (Stock 002728) (Harris et al., 1988). The Lkb1/ p53/ LSL-K-
RasG12D melanoma model has been previously described (Liu et al., 2012).
The B-RafV600E Pten/melanomamodel was obtained from Jackson Labora-
tories (Stock 013590) (Dankort et al., 2009). Following crosses with p16LUC, the
C3(1)TAg and TRIA models were 50% C57Bl/6 and 50% FVB/n. Em-Myc
p16LUC mice were fully backcrossed to albino C57Bl/6. The Lkb1/ p53/
LSL-K-RasG12D and B-RafV600E Pten/ melanoma models were analyzed on
a mixed background.
Syngeneic Tumor-Grafting Experiments
Cultured tumor cells were harvested, washed in Hank’s Balanced Salt Solution
(HBSS), and resuspended at the following concentrations in either matrigel
(M; BD Biosciences) or HBSS (H): 8.0 3 105 C3(1)Tag cells/100 ml injection
(M); 5.0 3 105 NT2 cells/100 ml (M); 5.0 3 105 PDAC1 cells/100 ml injection
(H); 5.0 3 105 endometrial cancer cells/100 mL injection (M); 5.0 3 105 KP53
cells/100 ml (H); 8.0 3 105 MEFs cells/100 mL (H). T11 cells were maintained
through serial passaging in wild-type BALB/c mice. For each passage, 5 3
105 cells resuspended in 100 ml of a 1:1 Matrigel:HBSS solution were injected
subcutaneously.
Bone Marrow Transplantation
Fifteen 10- to 12-week-old wild-type FVB/nmice were lethally irradiated (8 Gy)
by using a cesium source. The same day, bone marrow from a p16LUC hetero-
zygous FVB/nmouse was isolated, washed, and resuspended in HBSS. Cells
were injected intravenously at a concentration of 23 106 cells/100 ml injection.
Two to three weeks after transplant, mice were orthotopically injected with
tumor cells as described above. Prior to sacrifice due to advancing tumor
burden, mice were imaged to detect luciferase activity, and blood was har-
vested. RT-PCR genotyping of blood DNA was compared to a standard curve
of mixed wild-type and p16LUC heterozygous blood to determine chimerism
following transplantation. Blood chimerism was found to be >89% p16+/LUC
positive at the time of imaging.
PET Imaging
FDG-PET imaging was performed as previously described (Liu et al., 2011).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.cell.2012.12.010.
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